CrownBio and Pierre Fabre launched a drug discovery partnership

| By | Cancer Drugs, Drug Development, R&D
0
238

Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announced that it has been selected by Pierre Fabre Research Institute as one of their partners to advance their immuno-oncology drug discovery pipeline.

CrownBio boasts the world’s largest collection of patient-derived xenograft (PDX) models and is a leading provider of humanized solutions for immuno-oncology drug development. Leveraging these exclusive capabilities, CrownBio will engraft PDX models selected by Pierre Fabre into CD34+ humanized mouse models. These customized, humanized models will be used to accelerate Pierre Fabre’s innovative immuno-oncology drug discovery pipeline.

Laboratoires Pierre Fabre is a French multinational pharmaceutical and cosmetics company headquartered in the city of Castres, Midi-Pyrénées, France. Founded in 1962 by Pierre Fabre (1926-2013), the company is present in over 130 countries. The Pierre Fabre Ressearch and Development Center has been launched in 2010 to gather in one unique site all technologies and know of the Pierre Fabre Research and Development background.

Crown Bioscience International was founded in 2006 and is based in Taipei, Taiwan. The company offers a portfolio of translational platforms for oncology, and cardiovascular and metabolic diseases that provide insight and understanding about a drug’s efficacy, pharmacological profile, and patient response profile, as well as reduce failure in the clinic, and support the selection of the right patients for the right therapy.

SOURCE: globenewswire
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.